OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics. Its leading compound is an immuno-oncology therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The product pipeline includes both active (vaccine) and passive (monoclonal antibody and antibody drug conjugate) therapeutics.